Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bounce back from the 30% loss so far since Friday? Lol.
do you think the share count will increase in the future to help fund the company or do you think the company will find money to limit if not stop all dilution in the future?
I can't speak on the volume though I'd like to see a whole lot more of it than what we are now seeing. What I'd really like to see is funding and a confirmation date of clinical trials for the first IND approval.
That's not what I asked. I read it. I am asking what about it you thought was great. Fairly simple question.
And what info from the FDA is expected if I may ask.
would that not be insider info and illegal for friends and family to act upon?
Wow! Glad I didn't buy because now AMBS is down more than 30% from Friday's close and it will go down more! The Merger, which hasn't taken place yet, hasn't and won't do anything for the stock price. Why is that? Because it's a bogus merger that adds no value to AMBS!
yeah, Zacks revised that down from ~$14 all the way down to a $1 and that's a stretch it will ever reach that. That's actually pretty pathetic. And look at how the stock has tanked since Friday. Down over 30 percetn! OUCH!
It's hump day but no news. Looks like the call for news will have to be moved to tomorrow?
More important info that many newbies on here don't know about.
Amarantus is part of a biotech incubator in SF run by JNJ's Janssen's. It has been there for about 2 years. The idea gives Janssen a close look at cutting edge therapies etc with the hope that it might partner with some of these upstart biotechs.
Guess what? Janssen has seen absolutely NOTHING of interest from Amarantus.
Also know that Gerald's dad is the head scientist of Amarantus and part of his pay plan were bonuses for him to create at least 2 partnerships with Universities. Guess what? He failed at that. He couldn't gain any interest at all and obviously didn't get his bonus.
The one interesting partnership with a university it had concerning its MANF small molecule was with Dr. Urano at Washington U in St. Louis. That partnership no longer exists. Why is this important? Dr. Urano is the closest MANF has to getting real life results in patients who suffer from Wolfram's Syndrome. That's now dead in the water.
Here's the point. AMBS has burned, destroyed or mishandled almost everything its CEO touches or gets involved with. ESS was suppose to start clinical trials last year but, again and on cue, the company has missed that target date.
So on top of the horrible financial decisions the company has made, it has also shown it can't properly handle its pipeline.
The move of the Dx division to Avant is the prime example of this mishandling of their resources and pipeline. And the end result is the shareholders will not see any benefit of this. AMBS owning Avant stock does not, in any way, help AMBS share price.
People also should know that Grant is new to AMBS and took over for Jason Napadano who left Zacks. Jason no longer covers AMBS, even in private, when he realized that the CEO wasn't being honest with him.
Also know that so called analysts that cover AMBS like Zacks or See Thru Equity have received money from Amarantus. Besides, their judgement of AMBS has been incorrect at EVERY turn. Just look at See Thru Equity with their overly rosy targets for Amarantus while Amarantus was quickly dropping like a destroyer anchor. And the funny stuff continues with the ever so evident campaign.
It is too little too late unfortunately for Amarantus. Just minimal research and listening to yesterday's call, it is obvious that Amarantus is toast. They moved their Dx division off to Avant, another suspect OTC firm that has yet to show it can raise enough money to support not just its own diagnostic but now many others and it remains to be seen if the 3rd company can synergistically fit. It is hard enough to merge two groups but now it is three. The other very important part very poorly addressed by the CEO of AMBS is how this is going to benefit the shareholders of AMBS who already have been horribly misled by the CEO. Giving shares to Amarantus doesn't mean shareholders will benefit with an increased pps. Most legit Wall St. firms won't care if the parent company, Amarantus, is rotting from the inside out as it is now. And with talk of trying to do the same with ESS as was done with the Dx division, that leaves AMBS back with MANF which is no where near clinical trials. The CEO has failed to paint a path to where it can back on track. Is it no wonder why the Dx division doesn't have Amarantus' CEO anywhere near the management table? He's just an adviser. He has horribly mismanaged the company and no amount of internet "chatter" and online promotion will be able to save it.
It is just a delayed trade from earlier. Nothing else. It is sad to see the manipulation continue.
So what did the conference call say about MANF since you listened to it. I haven't had time yet.
So you are saying that the FDA does not need to get involved at all with approving or denying of Regen's therapies? If not, then that's great! Thanks.
What was said about MANF?
I have no idea where the price will go but you have to remember that this company relies on the good graces of the FDA. Biotechs are not for the faint of heart and if a clinical trial doesn't go well, companies can go out of business. I'm still hoping we will hear about some sort of news, funding or some sort of partnership, before the months out but I am not so sure that will happen.
100% Agree. Some are getting ahead of themselves with they excessive hype. I'm looking at a slow and steady thing here.
What is the twitter handle if you don't mind me asking?
Looks like the games aren't ending with this stock. Looking for some type of good news to reverse this sad trend.
Outside of hearing of any funding news is that the NIH is successful in identifying compounds and expands its relationship with Regen. That could have huge potential.
Ok, I get your m.o.
I just want to know why this company is trading where it is when the CEO had this to say
“We believe that sometime in the first half of 2016 we should have an IND filed on our small molecule and companies with an IND filed tend to be worth north of half a billion dollars.”
I was using the info from the La Mesa article I read that Dr. Koos has been funding the company by selling shares to friends and family. That is what I as trying to convey. But what about my other point? Why has this awesome pipeline not attracted any other source of funding via a big pharmaceutic or grant money in order to help fund clinical trials. All the patents in the world won't help if the company sits on its hands and don't perform clinical trials. Does that make sense?
As I do more research, I am really amazed by the pipeline. And that is why I don't understand why the company has no partnerships a drug company, grants or any type of funding yet. It makes no sense that the CEO is still relying on friends and family and the selling of shares.
There will have to be someone to start putting pressure on the bid for that to happen. And that's not happening. Unfortunately, the stock has had no stability since the run up. Again, this looks like the classic OTC manipulation in light of no news. There needs to be some sort of catalyst to get new investors interested in buying shares. That's not happening right now and why we are seeing such weakness.
Can you explain why you think it is going down in price if there is accumulation? Obviously every sell has a buy and vice versa but if there was accumulation, wouldn't the price be stable or going up due to increased demand? What I believe we are seeing is a dumping of shares and a price action due to weak demand for shares.
Thanks for the message with the email.
It looks like Lander is trying to get things lined up. I'm hoping that funding news is announced this month.
Ok, thanks. I'll read through their posts when I have time. But please remember, these are opinions of posters not facts or info from company insiders.
I hope you are right but the pattern of the stock from what I have seen shows no history of anyone wanting this stock except for a small band of investors. What isn't certain is if there ever will be a demand. That's the one thing with pink sheet stocks that make it more risky. The science will hopefully bring people to it.
Supply and demand. It doesn't matter if no one is selling if there is no demand for the stock. What we are now seeing is a lack of demand for the stock. I am hoping that changes soon with a catalyst. What do you think will create a frenzy of buying?
What isn't not true? That there isn't enough volume? This isn't a trading stock. Trading is thin and volume is low. For any stock to really make a move, you need liquidity. That's stock 101. Surely you can see that.
Unless Apple can maintain revenue growth, which I don't think it can, this remains to be a good short this year, imo.
Does PPHM have enough cash to last the year?
I agree. It's not a good sign that there is hardly any volume or trading. I would have thought volume would pick up and we'd start seeing several thousand of shares trading by now.
The current volume wouldn't necessarily support that theory with less than 40K traded unless those who are selling are selling for a really small gains.
This isn't going so well today. It appears the MMs are not actual humans but machines making these trades because no human MMs would be doing what we are seeing.
Good Morning,
What exact news is expected? I might try to buy more shares.
I don't understand? Are you saying that you don't believe the stock can become a 20 bagger to hit that $500 million market cap this year or you do? I'd jump for joy for that valuation but realistically, I don't see that happening. I've amassed a 10K share position. Not large but would be worth a lot if the stock hits that mark.
GLTY
Anyone eyeing an energy stock? Looks like we might be at the bottom for a bit longer but things will pick up.
That's a great read! I completely missed that article during my research. But do you honestly think the company is going to shoot up to half a billion dollar market cap that quickly, especially in this anti biotech climate we are in? Seems that valuation needs to be drastically paired down. How much did the stock price jump with the last fda approval? That might be a good comparison of how the stock will do. I'd be happy with a ~$50 to $80 mil dollar market cap. I think that would be reasonable but you never know with this crazy market.
GLTA